Experimental evidence for mTOR being a driving force for malignant progression in ΔS6 and ΔS6:ΔPTEN livers comes from studies showing that chronic activation of mTOR is sufficient to promote HCC in mice [105,106] and accelerates liver tumorigenesis in conjunction with hyperactivated PI3K/Akt [107]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.